603590 康辰药业
已收盘 05-22 15:00:00
资讯
新帖
简况
康辰药业涨10.01%,太平洋三周前给出“买入”评级
证券之星 · 05-21 16:28
康辰药业涨10.01%,太平洋三周前给出“买入”评级
异动快报:康辰药业(603590)5月21日13点7分触及涨停板
证券之星 · 05-21 13:15
异动快报:康辰药业(603590)5月21日13点7分触及涨停板
每周股票复盘:康辰药业(603590)股东会通过利润分配等六项议案
证券之星 · 05-17
每周股票复盘:康辰药业(603590)股东会通过利润分配等六项议案
康辰药业(603590)披露2025年年度股东会决议公告,5月14日股价下跌1.71%
证券之星 · 05-14
康辰药业(603590)披露2025年年度股东会决议公告,5月14日股价下跌1.71%
每周股票复盘:康辰药业(603590)回购进展及年度股东会将召开
证券之星 · 05-10
每周股票复盘:康辰药业(603590)回购进展及年度股东会将召开
康辰药业(603590)披露2025年年度股东会会议资料,5月7日股价上涨0.09%
证券之星 · 05-07
康辰药业(603590)披露2025年年度股东会会议资料,5月7日股价上涨0.09%
每周股票复盘:康辰药业(603590)股东户数增29.66%
证券之星 · 04-26
每周股票复盘:康辰药业(603590)股东户数增29.66%
康辰药业(603590)2026年一季报简析:营收净利润同比双双增长
证券之星 · 04-24
康辰药业(603590)2026年一季报简析:营收净利润同比双双增长
康辰药业最新公告:筋骨草总环烯醚萜苷片上市许可申请获受理
证券之星 · 04-24
康辰药业最新公告:筋骨草总环烯醚萜苷片上市许可申请获受理
康辰药业(603590)披露回购注销部分限制性股票及调整回购价格公告,4月23日股价下跌3.5%
证券之星 · 04-23
康辰药业(603590)披露回购注销部分限制性股票及调整回购价格公告,4月23日股价下跌3.5%
图解康辰药业一季报:第一季度单季净利润同比增长6.10%
证券之星 · 04-23
图解康辰药业一季报:第一季度单季净利润同比增长6.10%
4月20日康辰药业跌5.59%,汇添富医疗积极成长一年持有混合A基金重仓该股
证券之星 · 04-20
4月20日康辰药业跌5.59%,汇添富医疗积极成长一年持有混合A基金重仓该股
康辰药业最新公告:KC1036二线治疗晚期食管鳞癌关键性Ⅲ期临床研究获CDE批准
证券之星 · 04-09
康辰药业最新公告:KC1036二线治疗晚期食管鳞癌关键性Ⅲ期临床研究获CDE批准
每周股票复盘:康辰药业(603590)累计回购147.6万股
证券之星 · 04-05
每周股票复盘:康辰药业(603590)累计回购147.6万股
康辰药业(603590)披露股份回购进展公告,4月3日股价下跌3.18%
证券之星 · 04-03
康辰药业(603590)披露股份回购进展公告,4月3日股价下跌3.18%
每周股票复盘:康辰药业(603590)注销部分募集资金专户
证券之星 · 03-29
每周股票复盘:康辰药业(603590)注销部分募集资金专户
3月23日康辰药业跌6.95%,汇添富医疗积极成长一年持有混合A基金重仓该股
证券之星 · 03-23
3月23日康辰药业跌6.95%,汇添富医疗积极成长一年持有混合A基金重仓该股
康辰药业公布国际专利申请:“磺酰胺化合物或其可药用盐的晶型”
证券之星 · 03-22
康辰药业公布国际专利申请:“磺酰胺化合物或其可药用盐的晶型”
康辰药业(603590.SH):KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究获得CDE批准
智通财经 · 03-18
康辰药业(603590.SH):KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究获得CDE批准
康辰药业(603590)披露股份回购进展公告,3月5日股价上涨1.87%
证券之星 · 03-05
康辰药业(603590)披露股份回购进展公告,3月5日股价上涨1.87%
加载更多
公司概况
公司名称:
北京康辰药业股份有限公司
所属行业:
医药制造业
上市日期:
2018-08-27
主营业务:
北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。公司凭借核心产品“注射用尖吻蝮蛇血凝酶”(商品名“苏灵”)荣获第八批国家级制造业单项冠军企业认定。报告期公司被授予“北京制造业企业百强”、“北京高精尖企业百强”、“北京专精特新企业百强”等荣誉资质,并通过高新技术企业重新认定,公司总裁牛战旗获“密云区首批高层次人才”称号,企业实力再获认可。
发行价格:
24.34
{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":37.76,"timestamp":1779433200000,"preClose":39.22,"halted":0,"volume":10143927,"delay":0,"changeRate":-0.0372,"floatShares":158000000,"shares":159000000,"eps":1.0609,"marketStatus":"已收盘","change":-1.46,"latestTime":"05-22 15:00:00","open":38.88,"high":39.64,"low":37.75,"amount":390000000,"amplitude":0.0482,"askPrice":37.79,"askSize":2,"bidPrice":37.76,"bidSize":49,"shortable":0,"etf":0,"ttmEps":1.0609,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779672600000},"marketStatusCode":5,"adr":0,"adjPreClose":39.22,"symbolType":"stock","openAndCloseTimeList":[[1779413400000,1779420600000],[1779426000000,1779433200000]],"highLimit":43.14,"lowLimit":35.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":159010477,"isCdr":false,"pbRate":1.86,"roa":"--","peRate":35.592422,"roe":"1.46%","epsLYR":1.05,"committee":0.726908,"marketValue":6004000000,"turnoverRate":0.0641,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-05-26。","floatMarketCap":5975000000},"requestUrl":"/m/hq/s/603590/","defaultTab":"news","newsList":[{"id":"2637638308","title":"康辰药业涨10.01%,太平洋三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637638308?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:28","pubTimestamp":1779352116,"startTime":"0","endTime":"0","summary":"今日康辰药业涨10.01%,收盘报39.22元。2026年4月29日,太平洋研究员谭紫媚,张懿发布了对康辰药业的研报《康辰药业:核心产品增长稳健,创新管线快速推进》,该研报对康辰药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为61.07%。此外,中航证券研究员李蔚,中银证券研究员刘恩阳,苏雪儿近期也对该股发布了研报,同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","601099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637072809","title":"异动快报:康辰药业(603590)5月21日13点7分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2637072809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637072809?lang=zh_cn&edition=full","pubTime":"2026-05-21 13:15","pubTimestamp":1779340532,"startTime":"0","endTime":"0","summary":"证券之星5月21日盘中消息,13点7分康辰药业触及涨停板。其所属行业生物制品目前上涨。该股为创新药,医药,化学原料药概念热股,当日创新药概念上涨1.54%,医药概念上涨0.75%,化学原料药概念上涨0.55%。5月20日的资金流向数据方面,主力资金净流入219.04万元,占总成交额1.87%,游资资金净流入831.29万元,占总成交额7.09%,散户资金净流出1050.34万元,占总成交额8.96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100021436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636417064","title":"每周股票复盘:康辰药业(603590)股东会通过利润分配等六项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2636417064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636417064?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:36","pubTimestamp":1778960173,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,康辰药业报收于35.09元,较上周的35.62元下跌1.49%。本周关注点来自公司公告汇总:康辰药业2025年年度股东会审议通过利润分配预案等六项议案,全部获通过。北京康辰药业股份有限公司于2026年5月14日召开2025年年度股东会,会议由董事长刘建华主持,采用现场与网络投票相结合方式召开。北京康辰药业股份有限公司于2025年10月29日召开董事会及监事会,审议通过使用不超过2.6亿元闲置募集资金进行现金管理的议案,有效期12个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745087","title":"康辰药业(603590)披露2025年年度股东会决议公告,5月14日股价下跌1.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745087","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635745087?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:37","pubTimestamp":1778769433,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,康辰药业报收于35.65元,较前一交易日下跌1.71%,最新总市值为56.69亿元。该股当日开盘36.2元,最高36.63元,最低35.42元,成交额达8461.46万元,换手率为1.5%。近日,康辰药业发布《2025年年度股东会决议公告》。公告显示,公司于2026年5月14日召开2025年年度股东会,会议由董事长刘建华主持,采用现场与网络投票相结合方式召开。出席会议股东及代理人共333人,代表有表决权股份77,371,827股,占公司有表决权股份总数的49.1143%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634441453","title":"每周股票复盘:康辰药业(603590)回购进展及年度股东会将召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2634441453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634441453?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:21","pubTimestamp":1778350870,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,康辰药业报收于35.62元,较上周的35.4元上涨0.62%。本周,康辰药业5月8日盘中最高价报36.08元。本周关注点公司公告汇总:康辰药业将于2026年5月14日召开2025年年度股东会。公司公告汇总:截至2026年4月30日,康辰药业已累计回购1,476,204股,支付金额63,225,426.08元。康辰药业关于股份回购进展公告北京康辰药业股份有限公司于2025年10月15日召开董事会审议通过回购股份方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633126044","title":"康辰药业(603590)披露2025年年度股东会会议资料,5月7日股价上涨0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633126044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633126044?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:58","pubTimestamp":1778165893,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘,康辰药业报收于35.09元,较前一交易日上涨0.09%,最新总市值为55.8亿元。近日,康辰药业发布《2025年年度股东会会议资料》公告。公告显示,公司将于2026年5月14日召开2025年年度股东会,会议审议2025年度董事会工作报告、利润分配预案、董事及高管薪酬管理制度修订、续聘华兴会计师事务所为2026年度审计机构、回购注销部分限制性股票等议案,并听取独立董事述职报告及高级管理人员薪酬执行情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630044018","title":"每周股票复盘:康辰药业(603590)股东户数增29.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630044018","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630044018?lang=zh_cn&edition=full","pubTime":"2026-04-26 04:06","pubTimestamp":1777147572,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,康辰药业报收于35.25元,较上周的38.61元下跌8.7%。本周,康辰药业4月20日盘中最高价报38.59元。股本股东变化股东户数变动截至2026年3月31日,康辰药业股东户数为1.52万户,较2025年12月31日增加3486.0户,增幅达29.66%。回购注销后,公司总股本将由159,010,477股减少至159,005,477股。康辰药业关于公司在2026年AACR年会展示创新药KC1086和KC1101临床前研究数据的公告2026年4月21日,公司在AACR年会上以壁报形式首次公布自主研发创新药KC1086和KC1101的临床前研究数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629615840","title":"康辰药业(603590)2026年一季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2629615840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629615840?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:20","pubTimestamp":1777040433,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期康辰药业发布2026年一季报。根据财报显示,康辰药业营收净利润同比双双增长。截至本报告期末,公司营业总收入2.15亿元,同比上升1.35%,归母净利润4721.36万元,同比上升6.1%。本次财报公布的各项数据指标表现尚佳。然而去年的净利率为18.51%,算上全部成本后,公司产品或服务的附加值高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400064944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629819813","title":"康辰药业最新公告:筋骨草总环烯醚萜苷片上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2629819813","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629819813?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:37","pubTimestamp":1777019854,"startTime":"0","endTime":"0","summary":"康辰药业公告称,公司近日收到国家药监局下发的《受理通知书》,公司拥有自主知识产权的中药创新药筋骨草总环烯醚萜苷片药品上市许可申请获得受理。该药品是首个针对“盆腔炎性疾病后遗症慢性盆腔痛”的中药1.2类创新药,主要用于治疗盆腔炎性疾病后遗症引起的慢性盆腔痛。此前,该药品已完成Ⅲ期临床试验,主要研究终点达到方案预设的优效界值,安全性和耐受性良好。公司将积极推进药物研发进度,并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400050559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629688249","title":"康辰药业(603590)披露回购注销部分限制性股票及调整回购价格公告,4月23日股价下跌3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629688249","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629688249?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:55","pubTimestamp":1776938109,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘,康辰药业报收于36.07元,较前一交易日下跌3.5%,最新总市值为57.36亿元。该股当日开盘37.4元,最高37.4元,最低35.6元,成交额达1.26亿元,换手率为2.21%。公司于近日披露《关于回购注销部分激励对象已获授但尚未解除限售的限制性股票及调整回购价格的公告》。鉴于公司已完成2024年度权益分派,回购价格由16.73元/股调整为16.13元/股。本次回购资金总额为80,650元,全部来源于公司自有资金。回购注销后,公司总股本将由159,010,477股减少至159,005,477股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300049441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629219200","title":"图解康辰药业一季报:第一季度单季净利润同比增长6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629219200","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629219200?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:56","pubTimestamp":1776880579,"startTime":"0","endTime":"0","summary":"证券之星消息,康辰药业2026年一季报显示,一季度公司主营收入2.15亿元,同比上升1.35%;归母净利润4721.36万元,同比上升6.1%;扣非净利润4606.66万元,同比上升4.94%;负债率13.97%,投资收益253.99万元,财务费用186.06万元,毛利率89.81%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300003801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628748283","title":"4月20日康辰药业跌5.59%,汇添富医疗积极成长一年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628748283","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628748283?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:16","pubTimestamp":1776672975,"startTime":"0","endTime":"0","summary":"证券之星消息,4月20日康辰药业跌5.59%,收盘报36.45元,换手率3.21%,成交量5.08万手,成交额1.88亿元。重仓康辰药业的前十大公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗积极成长一年持有混合A。汇添富医疗积极成长一年持有混合A目前规模为17.45亿元,最新净值0.7403,较上一交易日下跌1.76%,近一年上涨27.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000021274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626002799","title":"康辰药业最新公告:KC1036二线治疗晚期食管鳞癌关键性Ⅲ期临床研究获CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626002799","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626002799?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:20","pubTimestamp":1775726438,"startTime":"0","endTime":"0","summary":"康辰药业公告称,公司自主研发的KC1036片获得国家药品监督管理局药品审评中心批准,开展“评估KC1036对比研究者选择的化疗治疗既往经一线免疫检查点抑制剂联合化疗方案失败的晚期复发或转移性食管鳞癌受试者”的关键性Ⅲ期临床研究。KC1036为公司拥有全球知识产权的化学药品1类创新药,通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。这是KC1036在食管鳞癌领域获批开展的第二个关键性Ⅲ期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900027414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619950","title":"每周股票复盘:康辰药业(603590)累计回购147.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619950?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:07","pubTimestamp":1775329630,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,康辰药业报收于37.74元,较上周的36.76元上涨2.67%。本周,康辰药业4月2日盘中最高价报39.71元。截至2026年3月31日,已累计回购1,476,204股,占公司总股本的0.93%,支付金额63,225,426.08元,回购价格区间为36.42元/股至51.40元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651444","title":"康辰药业(603590)披露股份回购进展公告,4月3日股价下跌3.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624651444?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:16","pubTimestamp":1775211378,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,康辰药业报收于37.74元,较前一交易日下跌3.18%,最新总市值为60.01亿元。该股当日开盘38.98元,最高38.98元,最低37.4元,成交额达9590.51万元,换手率为1.59%。康辰药业于2026年4月3日发布《关于股份回购进展公告》。公告显示,公司于2025年10月15日召开董事会审议通过回购股份方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励。2026年3月回购359,900股,支付金额13,509,851.00元。本次回购符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333468","title":"每周股票复盘:康辰药业(603590)注销部分募集资金专户","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333468?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:40","pubTimestamp":1774730423,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,康辰药业报收于36.76元,较上周的36.42元上涨0.93%。本周,康辰药业3月27日盘中最高价报36.96元。康辰药业当前最新总市值58.45亿元,在生物制品板块市值排名38/51,在两市A股市值排名2998/5191。公司公告汇总康辰药业完成部分募集资金专户及现金管理专用结算账户的注销。中国民生银行北京德胜门支行募集资金专户与财通证券募集资金投资产品专用结算账户余额为零,现已销户,相关监管协议同步终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621767775","title":"3月23日康辰药业跌6.95%,汇添富医疗积极成长一年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621767775","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621767775?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:29","pubTimestamp":1774254558,"startTime":"0","endTime":"0","summary":"证券之星消息,3月23日康辰药业跌6.95%创60日新低,收盘报33.89元,换手率1.99%,成交量3.15万手,成交额1.09亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗积极成长一年持有混合A。汇添富医疗积极成长一年持有混合A目前规模为17.45亿元,最新净值0.6638,较上一交易日下跌1.54%,近一年上涨17.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621794475","title":"康辰药业公布国际专利申请:“磺酰胺化合物或其可药用盐的晶型”","url":"https://stock-news.laohu8.com/highlight/detail?id=2621794475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621794475?lang=zh_cn&edition=full","pubTime":"2026-03-22 05:42","pubTimestamp":1774129334,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示康辰药业(603590)公布了一项国际专利申请,专利名为“磺酰胺化合物或其可药用盐的晶型”,专利申请号为PCT/CN2025/121064,国际公布日为2026年3月19日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来康辰药业已公布的国际专利申请2个。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了2049.84万元,同比减12.01%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620023771","title":"康辰药业(603590.SH):KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究获得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620023771","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620023771?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:51","pubTimestamp":1773831086,"startTime":"0","endTime":"0","summary":"II期临床研究结果显示,KC1036在晚期复发或转移性胸腺癌中展现突出的抗肿瘤疗效且安全性可控。公司于近日获得CDE批准开展KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究,这是继三线治疗晚期食管鳞癌Ⅲ期临床研究之后,KC1036第2个获批开展关键性Ⅲ期临床研究的适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDE","LU1223082519.USD","LU1223083913.SGD","BK0239","603590","BK4017","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617517158","title":"康辰药业(603590)披露股份回购进展公告,3月5日股价上涨1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517158","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517158?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:21","pubTimestamp":1772702497,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘,康辰药业报收于39.87元,较前一交易日上涨1.87%,最新总市值为63.4亿元。该股当日开盘40.0元,最高40.3元,最低39.34元,成交额达7088.25万元,换手率为1.12%。康辰药业于2026年3月5日发布《关于股份回购进展公告》。公告显示,公司于2025年10月15日召开董事会审议通过回购股份方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励。本次回购符合相关法规及公司方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500027998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779572411642,"stockEarnings":[{"period":"1week","weight":0.0761},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.1042},{"period":"6month","weight":-0.1169},{"period":"1year","weight":0.2705},{"period":"ytd","weight":-0.0501}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0076},{"period":"6month","weight":0.0725},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15241人(较上一季度增加29.66%)","perCapita":"10381股","listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","registeredCapital":"15901万元","survey":" 北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。公司凭借核心产品“注射用尖吻蝮蛇血凝酶”(商品名“苏灵”)荣获第八批国家级制造业单项冠军企业认定。报告期公司被授予“北京制造业企业百强”、“北京高精尖企业百强”、“北京专精特新企业百强”等荣誉资质,并通过高新技术企业重新认定,公司总裁牛战旗获“密云区首批高层次人才”称号,企业实力再获认可。","listedPrice":24.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}